Objectives: Assessing the safety and efficacy of immune checkpoint inhibition in risky cancer patient subgroups: pre-existing organ failure, elderly, presence of auto-immune disease, transplanted patients and brain metastasis treated with immune checkpoint inhibitors. Methods: PubMed, Web of Science and Google scholar databases were searched for English articles published prior to February 2019. Search terms used were organ failure, dialysis, elderly, organ transplant, liver disease, auto-immune disease, immunosuppression, and brain metastasis. Results: Our literature data indicate that immune checkpoint inhibition in the majority of these subpopulations can be administered safely without any loss of efficacy. These data are mostly based on case-reports as only a minority of high-risk patients were included in (the earliest) clinical trials. Validation of these results is necessary on a larger scale. Conclusion: Future trials should not automatically exclude aforementioned patient groups but alter the study design and make their inclusion possible, since more data are needed to answer several remaining questions in these populations. Especially since ICI appears to be safe to administer in these patients.
Introduction
Immune checkpoint inhibition (ICI) has been validated as a standard treatment regimen in hematologic malignancies and numerous solid cancer types. Well-known immune checkpoints are cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) (and its ligand PD-L1) [1] . These functions as negative regulators of the T-cell immune function, restraining overactivity of the immune system by inducing T cell anergy and/or apoptosis. Inhibition of these immune checkpoints thus results in an overactivity of the immune system by enhancing a T-cell response and, subsequently, an anti-tumor response by increased tumor antigen recognition [2] . On the other hand, the immune checkpoint pathways have an important immune regulatory function that, when suppressed by ICI, induce autoimmune phenomena that can affect every organ. Indeed, ICI has a distinct toxicity profile and although generally well tolerated in most patients, some experience rare, life-threatening side-effects (immune-related adverse events, irAEs Table 1 ). As indications for ICI are broadening, this implies that a larger and heterogeneous population will be treated. This will confront the physician not only with a more challenging population to treat, but also with an increasing incidence of irAEs that need immediate and adequate medical attention [3] . Numerous clinical trials are ongoing to assess the efficiency and safety of ICI for various malignancies, but data are lacking information on high-risk patient groups that are prone to develop more and/or worse irAEs, and hence therapy-related worsening of their general health status. In this review, we will discuss some risky patient groups and the current knowledge of ICI-treatment in these settings. We will consider patients with pre-existent organ injury or failure, elderly (active) autoimmune disease(s) (AID), transplanted patients (kidney or liver) and patients suffering from brain metastasis.
Method

Search strategy
A comprehensive search was performed on Google scholar, Pubmed and Web of Science for selecting relevant literature and studies from inception of ICI until February 2019. A set of keywords and combination of keywords were applied during the literature study: 'ICI' or 'immune checkpoint inhibition' was combined with any of the following terms: 'organ failure', 'dialysis', 'elderly', 'organ transplant', 'liver disease', 'auto-immune disease', 'immunosuppression', and 'brain metastasis'. In review articles, the reference list was consulted and using the snowball effect, other English studies or articles were added. The earliest studies were published in February 2015 and all articles were initially screened by title and abstract. Articles were withheld when each relevant patient group was treated with one or more immune checkpoint inhibitors, when authors used the standardized evaluation of tumor response to the ICI according to the RECIST/iRECIST guidelines and when adverse events were graded based on the National Cancer Institute Common Toxicity Criteria (version 4.0 or later).
Results
Organ comorbidities
Kanz et al. [17] performed a multicenter retrospective analysis to detect changes in organ dysfunction and evaluate response rate (RR), progression-free survival (PFS) and irAE-incidence in anti-PD-1 treated cancer patients with baseline organ dysfunction. The latter was defined as renal insufficiency (glomerular filtration rate of ≤30 ml/min or serum creatinine level ≥2 mg/dl), cardiac dysfunction (left ventricular ejection fraction ≤45%) or hepatic dysfunction (serum transaminases or bilirubin >3x upper limit of normal or evidence of cirrhosis on imaging). They reported no significant increase in irAEincidence. Also, worsening organ dysfunction occurred sporadically and resolved spontaneously with supportive care in all cases. The authors concluded that anti-PD-1 administration can be considered safe in patients with organ dysfunction, provided appropriate clinical monitoring is performed during the treatment period. Hertz et al. [18] described four case-reports of patients with chronic kidney failure who all were treated with ICI (anti-CTLA-4/anti-PD-1). None of these patients experienced further deteriorating kidney function during treatment, nor was any kidney toxicity observed. One patient-developed grade 2 polyneuropathy, which however resolved after adequate therapy was started.
The data from our own research group (unpublished) also indicate no significant signs of kidney damage during ICI treatment (immune-related nephritis were not included in the analysis), based on serum creatinine, Cystatin C, proteinuria, albuminuria, immunoglobinuria (IgG) measured in 18 mRCC patients. Statistical analysis needs to be finalized but a first glance at the data revealed no significant alterations in these markers during ICI treatment [19] .
Next, not many cases have been reported of endstage renal disease (ESRD) patients undergoing dialysis and receiving ICI treatment. Two ESRD patients suffering from mCCRCC were administered nivolumab. Both patients had a significant anti-tumor response according to iRECIST-criteria and did not experience any irAEs [20] . Cavalcante et al. [21] described another two ESRD patients with metastatic melanoma who received and benefited from ipilimumab treatment: a partial response was noted in one patient while the second patient achieved complete remission of the disease. Toxicity was acceptable, though one patient encountered a grade 3 skin irAE (bullous pemphigoid) which resolved under systemic corticosteroids. Lastly, a single-center case series from Park et al. [22] treated four ESRD patients with PD-1 inhibitors: two patients with mRCC and two patients with unresectable cutaneous squamous cell carcinoma. Although all patients experienced a significant anti-tumor response according to iRECIST-criteria, toxicity was moderately high. Two incidences of grade 2 fatigue, one grade 2 rash, one grade 3 pneumonitis and even a fatal incidence of grade 4 acute encephalitis occurred.
In short, the available literature shows that hepatic, renal and cardiac comorbidities nor need for dialysis should be an absolute contra-indication for administering ICI in cancer patients, provided the standard of care and organ function monitoring is adequately performed.
Elderly and poor performance status
Not only are elderly more susceptible of developing organ comorbidities (hypertension, hypercholesterolemia, chronic kidney disease), assumptions have been made that they are affected by immunosenescence, an age-related functional decline in the immune system. This may be associated with a decreased auto-immunity, a significant functional (anti-cancer) immunodeficiency and a dysregulation of the different immune system components, both innate and acquired. In a 2016 systematic review and meta-analysis by Nishijima et al. [23] ICI efficacy and tolerance was compared between young and old patients (cut-off 65/70 years). They concluded that tolerance of immunotherapy in older patients is similar compared to young patients and that disease-free survival (DFS) and overall survival (OS) were consistently better in both treated groups. Regarding response, Nishijima et al. made a pre-specified subgroup analysis by age and type of ICI treatment (anti-PD-1 agents vs. anti-CTLA-4 agents) of four trials each. Elderly (≥65) years treated with anti-CTLA-4 agents had a significant increase in OS as well as younger patients (<65 years). In the anti-PD-1 treated patients, four trials reported an increased survival outcome in patients <65 years and 65-75 years old, but not in ≥75-year-old patients. This is probably attributed to a lack of statistical power and heterogeneity of the used populations [23] . Contradictory, a retrospective study from Ibrahim et al. [24] reported a significantly higher ORR and PFS in elderly (≥75 years) with metastatic melanoma treated with pembrolizumab in comparison to those patients treated with nivolumab or ipilimumab. Toxicity was similar in all ICI treated patients.
In patients with poor performance status (PS), a metaanalysis of Bersanelli et al. [25] stated that PS does not interfere with ICI efficacy as an identical OS benefit was noted in patients with poor (ECOG) PS (= 1) compared to normal PS (= 0). As patients with a PS = 2 were mostly refused in participating in clinical trials with ICI, data regarding this subgroup is scanty. However, a recent multi-variant analysis in nivolumab treated NSCLC patients observed that PS was an independent prognostic factor in OS when comparing patients with PS = 1 and PS = 2 versus patients with PS = 0 [26] . Then again, a retrospective study from Muchnik et al. [27] concluded that PS primarily affects OS in ICI treated NSCLC patients as older (≥70 years): patients with PS = 0 or PS = 1 were observed to have similar benefits from ICI when compared with young patients in healthier conditions, while older patients with PS ≥2 had worse outcome despite ICItreatment. All authors conclude that large-scale prospective studies remain necessary to assess safety and efficacy of ICI in these fragile subpopulations.
Organ transplant patients
Administration of ICI in organ-transplanted patients is another debatable subject. The PD-1 and CTLA-4 pathways are vital down regulators of auto-immunity as they restrict T-cell activation. Thus, activation of these pathways by ICI could enhance or trigger organ transplant rejection. Also, transplanted patients have a lasting need for chronic immunosuppression [28] . For these reasons, organ-transplanted patients are excluded from studies in which treatment with ICI is indicated. Chae et al.'s [29] research suggest that CTLA-4 inhibitors are relatively safe in patients with solid organ transplant, as only one of six patients experienced allograft rejection. PD-1 inhibitors on the other hand, are significantly more prone to trigger allogeneic graft rejection, as this occurred in four out of eight patients [29] . Another case-report of a patient with a pre-emptive renal allograft transplant and under chronic immunosuppression (prednisone, 10 mg), who was diagnosed with metastatic melanoma, showed that treatment with nivolumab resulted in renal allograft rejection 1 week after administration. Nivolumab treatment was ceased but renal function remained irreversibly impaired, leading to urgent dialysis need. Nivolumab treatment was again introduced and triggered an important regression of tumor burden. Furthermore, no irAEs occurred after the patient became dialysis dependent [30] .
There is still insufficient evidence to presume that ICI is safe in allogeneic-transplanted cancer patients. Abovementioned results tend to point out that CTLA-4 inhibitors are more favorable than anti-PD-1 in this population, though these findings should be further validated in a larger prospective studies., Authors concur that the gain in life expectancy with ICI treatment should be weighed up against the possible and probable occurrence of irAE development and organ rejection, and this should be discussed with patient and organ specialist [23] .
Auto-immune diseases
Cancer patients with an active autoimmune disease (AID) are a challenging population to treat with ICI. These patients are almost invariably excluded from clinical trials because of possible exacerbation of the preexisting auto-immune disease, increased incidence of (more severe) irAEs and the theoretical projection of reduced cancer response rate due to intake of chronic immunosuppressants.
A meta-analysis from Abdel-Wahab et al. [31] analyzed case reports of cancer patients (N = 123) with auto-immune diseases who were subjected to treatment with ICI. They found that 50% had AID exacerbation and 34% had de novo irAEs, with colitis and hypophysitis being most frequently reported.
Nine percent of patients experienced both. However, this did not result in a permanent discontinuation of the ICI in any of the subjects.
Recently, a retrospective analysis of 46 NSCLC (stage IIIb/IV) patients with AID, treated with anti-PD-1 was published. The authors concluded that the incidence of worsening AID-related symptoms during ICI was relatively low, as only 17% of patients experienced exacerbation of their AI-status. Twenty-six percent of patients developed one or more irAEs nondirectly associated to their AID, but no grade 3 or 4 irAEs were reported. Three patients had to discontinue anti-PD-1 treatment permanently due to intolerable toxicity. In retrospect, the irAE incidence in patients with AID does not differ significantly from an anti-PD-1 treated populations without AID [32] . These results were somewhat contradicted by Danlos et al. [33] as anti-PD-1 treated cancer patients with pre-existing AID did encounter more irAEs and flare-ups when prospectively compared to AID-free patients. Though grade ≥2 irAEs incidence was comparable with other investigations. No differences in OS were observed in both patient groups.
Menzies et al. [34] also reported an increase of immune toxicity during anti-PD-1 treatment in melanoma patients with active AI disease or early treatment with ipilimumab, although these toxicities are perceived as mild, easily manageable under adequate corticosteroid treatment, and did not require therapy discontinuation. Importantly, it should be mentioned that significant clinical response rates were achieved in this patient population. We conclude that some discrepancies regarding incidence of ICI toxicity and AID flare-ups exist between different studies, though safety and efficiency can be similar in AID-patients as non-AID patients when adequate clinical monitoring is warranted.
Brain metastasis
Brain metastatic (BM) patients (here we focus on asymptomatic patients, treated with radiotherapy or under minimal dose systemic steroids) have a poor prognosis and are often excluded from enrolment in trials with immune checkpoint blockers. The checkmate 017 and 057 trials compared treatment with docetaxel or nivolumab in previously treated NSCLC with BM and found no OS benefit of nivolumab over docetaxel in this subgroup. (HR: 1.04, 95% CI: 0.62-1.76) [35] . On the other hand, the OAK study compared atezolizumab with docetaxel in platinum-failed patients with advanced/metastatic NSCLC, including supratentorial metastatic patients. An increased survival outcome of atezolizumab over docetaxel was noted (HR: 0.54, 95% CI: 0.31-0.94) [31] . Both ICI demonstrated a tolerable safety profile that was comparable to prior studies and also to docetaxel [35, 36] .
An abstract from Albiges et al. [37] described a prospective analysis (NIVOREN) to assess the response to nivolumab in BM RCC. This was the first study that included RCC-patients with BM, irrespective of local control for BM. Nivolumab proved more efficient in BM patient without prior local treatment compared to pre-treated patients, and most patients in the latter group required local treatment due to progression. The six-months brain progression freesurvival was 44.8% in previously treated patients in comparison to 24.5% in non-treated patients.
Regarding melanoma, an Australian, multicenter open-label, randomized phase II-study from Long et al. [38] investigated the efficacy of ICI in melanoma patients with active BM. Eventually, one concluded that the combination ipilimumab/nivolumab as well as nivolumab in monotherapy showed intracranial response in BM melanoma, although the combination being superior compared to nivolumab in monotherapy: in asymptomatic BM patients, a 46% intracranial response rate with the combination ipilimumab/nivolumab was noted, while this was 20% in patients that were administered nivolumab alone. The six-month progression-free survival (PFS) was 53% and 20%, respectively [38] . The Checkpoint 204 trial confirmed these results, as an intracranial response in 41/75 patients (55%) treated with ipilimumab/nivolumab combination was observed, and a 6 months PFS of 67% was noted [39] . Toxicity was obviously higher in the nivolumab/ipilimumab combination cohort than in the nivolumab monotherapy cohort, with a 97% and 50-68% irAE prevalence, respectively, while grade 3-4 irAEs were present in 54% and 13-16%, respectively [38] .
Discussion and conclusion
This review focuses on the safety and efficiency of ICI (anti CTLA-4, anti PD1 and anti PD-L1) in subgroups of cancer patients: those with fragile health conditions, those considered to have an increased risk to therapyinduced auto-immune phenomena and other adverse events, patients with brain metastasis and patients that are excluded from inclusion in the larger ICI trials because of the abovementioned conditions. Evidently, there remain subpopulations that have not been addressed sufficiently in literature, and hence have not been discussed in this review paper (immunodeprived patients, e.g. HIV, patients with chronic infections such as hepatitis B/C or latent tuberculosis, ICI during pregnancy)
Regarding (non-auto-immune related) organ comorbidity and ICI, it has been described in the current literature that anti-PD-1 is considered safe in these patients. The effectiveness of ICI in patients with renal impairment has also been examined in a number of clinical trials. Preliminary results indicate similar response rates in ICI treated cancer patients with or without renal impairment. However, these data need to be further validated in the future [40] [41] [42] . Exacerbation of baseline organ dysfunction was never found to be attributable to ICI treatment, and worsening could be reversed by standard supportive measure. It must be clear that the risk of all other ICI should also be assessed, especially when administering an ICI combination therapy.
We do believe that the use of ICI is a valid and safer option in comparison to chemotherapy in patient with multiple, complex organ comorbidities. Although only a handful of case reports exist, these data suggest that ESRD patients undergoing dialysis may indeed benefit from ICI treatment as the majority of patients had significant anti-tumor response. A plausible explanation is that the high molecular weight of ICI prevents them from being removed during dialysis, though further pharmacokinetic analysis is obligatory. Toxicity was quite manageable in this patient group, but some subjects did develop severe irAEs (two grade 3 and one fatal grade 4). Based on the limited sample size, there is insufficient evidence to state that toxicity of ICI is higher in ESRDpatients than in patients with normal renal function. From a theoretical point of view, there is also no reason to suspect higher risk of ICI toxicity in this population though caution remains well advised. Current and future prospective studies will eventually provide us with an adequate answer.
Based on the current literature, ICI may be carefully considered in transplanted patients, though this should always be in consent with the patient as the risk of inducing organ rejection when administering ICI exists and may have life-threatening consequences [31] .
Management of patients with auto-immune disease or patients under chronic immunosuppression remains delicate when considering treatment with immune checkpoint inhibition. Some studies acknowledge active autoimmune disease as a contraindication for immune checkpoint inhibition, but a > 2-year interval of only inactive disease or chronic treatment with low-dose corticosteroids (e.g. prednisolone ≤10 mg/day) could be considered safe [26] . Either way, this field of research requires more robust, longterm prospective studies to fully appreciate the interactions between immune checkpoint inhibition and auto-immune disease and/or chronic immunosuppression [32] .
As mentioned earlier, elderly patients are subjected to an increased risk of developing (age-related) comorbidities but also immunosenescence, which could limit tumor recognition and elimination by diminished T-cell mediated immunity and therefore, a decreased antitumor immune response [23] . Theoretically, this could imply that immune checkpoint inhibitors can be less efficacious in this particular group. Based on the current available literature there seems to be no signs of higher toxicity range in the elderly. Elderly (≥65 years) did obtain a similar survival benefit from ICI compared to younger patients, but some discrepancies in literature exist considering the use of anti-PD-1 agents in ≥75 years old patients. This needs to be further elaborated [23, 24] . Regarding ECOG PS, the clinical benefit from ICI in patients with PS ≥ 2 seemed to be inferior compared to PS < 2, while other research states that PS is an independent prognostic factor. Nonetheless, there is a high need for large prospective studies that do not exclude these vulnerable patient groups from ICI treatment [25] [26] [27] .
It should also be mentioned that even minor ICI induced toxicity in these patients with worse baseline organ function can induce higher risk of major organ dysfunction. Nonetheless, age and frailty (PS ≤ 2) should not guide physicians to disallow ICI in patients with metastatic malignancies as they still may truly benefit from this therapy. Future trials should never neglect these subpopulations, but we advise caution and ensure extra medical monitoring during treatment with ICI [43] .
These last few years, more and more brain metastatic patients have been treated with immune checkpoint inhibitors, with varying results. Although this barrier has now been overcome and more and more positive results reported, brain metastatic patients presenting with active, untreated disease and/or experiencing clinical symptoms are still excluded from most clinical trials due to the poor prognosis and the risk of early death. Current state-of-the-art indeed shows a significant trend towards intracranial response and an increased progression-free survival with immune checkpoint inhibitors (with results in melanoma being the most promising, especially the anti-CTLA4anti PD1 combination). Nevertheless, high-risk brain metastatic patients (symptomatic or evidence of leptomeningeal metastasis) are generally excluded from most studies which limit our conclusions regarding ICI in brain metastatic patients.
Immune checkpoint inhibitors have proven to be of major impact in current cancer therapeutic strategy for various cancers. Based on the current data available, we can state that ICI treatment in the above described high-risk subpopulations may be considered efficacious and safe, but the all-encompassing answer still has to be found. We encourage clinicians and investigators to adopt a personalized approach for each cancer patient by assessing the risks and benefits of (not) receiving ICI. Hence, future trials should not automatically exclude these high-risk patients but should adapt the study design so that more info becomes available about these patients, that transcends the limits of case reports. In this point of view, the SAUL trial is a large prospective, multi-centric, single-arm study of atezolizumab for locally advanced or metastatic urothelial carcinoma of the urinary tract that enrolled a broader patient population including patients with an ECOG PS of 0-2, stable CNS metastasis, AID, active steroid treatment, renal dialysis requirement or creatinine clearance of <15 ml/min. This is a research design that we encourage clinicians to implement in the near future [44] .
Additionally, biomarker development for detection of irAEs is an area of investigation that is extensively being studied by various research groups. Although this topic falls beyond the scope of this review, development of adequate biomarkers could aid the oncologist in guiding his patient to a more beneficial outcome during ICI treatment and is therefore highly recommended [45] .
